Accelr8 to Receive Award for ICAAC Presentation
July 18 2011 - 7:30AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
that the company received notice of an ICAAC Program Committee
Award in the area of Clinical Microbiology and Diagnosis. The award
recognizes the “outstanding presentation of an abstract accepted by
ICAAC” for the 51st ICAAC to be held in Chicago on September 17-20,
2011. The award will be presented at the meeting. The presentation
title is “Same-Shift ID Directly from Respiratory Specimens by
Automated Microscopy.” It will report results from a study using
Accelr8’s BACcel™ rapid diagnostic system in collaboration with
investigators at the Barnes-Jewish Hospital in St. Louis.
Accelr8 will announce the study results at the time of the
presentation.
ICAAC (www.icaac.org) is the annual Interscience Conference on
Antimicrobial Agents and Chemotherapy. Organized by the American
Society for Microbiology (www.asm.org), ICAAC is a major global
congress for Clinical Microbiology and Infectious Diseases
Medicine.
In additional news, Accelr8 received notice of issuance for a
Japanese patent on the BACcel™ system. The new patent joins
previously issued US and international patents to broaden Accelr8’s
global patent coverage for the BACcel™ system.
According to David Howson, Accelr8’s president, “We are honored
by the recognition from ICAAC’s review committee. It reflects the
BACcel™ system’s potential importance in Clinical Microbiology. Our
culture-free methods have repeatedly demonstrated the unprecedented
ability to quantitatively identify multiple pathogens directly from
patient specimens in less than 2 hours. Our pilot clinical studies
pass the ‘real specimen’ hurdle that continues to stymie new
attempts to replace multi-day culturing. The BACcel™ system
continues to widen its lead in helping to fight the worsening
global antibiotic resistance pandemic.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024